Physician profile
Shannon E Burke
NPI 1245686401
$7,668.41
in general payments reported to CMS, 2019-2025
20 companies · $5,842 in 2025
The $5,842 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $123 · 2022: $217 · 2023: $465 · 2024: $899 · 2025: $5,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614 · Education: $2,540 · Travel and Lodging: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,614.21 |
| Education | $2,539.90 |
| Travel and Lodging | $1,051.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,670.66 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $893.29 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $769.92 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $314.04 | 2025 | |
| United Therapeutics Corporation | $292.29 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.78 | 2019-2025 | Jascayd, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $225.44 | 2021-2025 | Glassia |
| Merck Sharp & Dohme LLC | $204.65 | 2024-2025 | Winrevair |
| Baxter Healthcare | $202.56 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Metaneb System, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $184.39 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $146.09 | 2025 | Yupelri |
| Verona Pharma, INC. | $137.29 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $104.63 | 2023-2024 | Yupelri |
| Pfizer INC. | $64.58 | 2022-2023 | |
| Medtronic, INC. | $48.82 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $39.38 | 2025 | Purified Cortrophin Gel |
| Tactile Systems Technology INC | $34.64 | 2025 | Flexitouch Plus, Nimbl |
| Amgen INC. | $21.80 | 2024 | Tavneos |
| Atricure, INC. | $20.25 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $15.91 | 2025 | Uptravi, Opsumit, Opsynvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.